医疗和牙科

Triastek and Eli Lilly partner to 3D print gastrointestinal drugs

Chinese drug 3D printing firmTriastekhas announced a partnership with global pharmaceuticals companyEli Lilly研究和开发用于胃肠道的3D印刷口服药物。

Specifically, the project will leverage Triastek’s proprietary Melt Extrusion Deposition (MED) technology to fabricate programmed drug release profiles to target specific areas of the human digestive system.

Dr. Senping Cheng, founder and CEO of Triastek, said, “The collaboration between Triastek and Lilly is a great example of applying MED® technology for improving the oral delivery of drugs. We envision that the MED® technology of Triastek can be used to solve the challenges in formulations leading to the development of clinically valuable products for our global partners.”

Triastek的Med 3D打印技术。图片通过Triastek。
Triastek的Med 3D打印技术。图片通过Triastek。

Triastek和Med 3D打印

Triastek成立于2015年,其整个业务围绕3D印刷固体剂型药物。该公司已经完成迄今为止六轮融资,,,,with investors such as塔斯利控股小组,,,,Morningside风险投资,,,,火山冒险,,,,Dalton Venture,,,,Yunqi合作伙伴,,,,Matrix Partners China, 和更多。

The firm’s MED 3D printing technology provides an end-to-end method of manufacturing a wide variety of novel dosage form designs. The extrusion-based process works by mixing, melting, and depositing active ingredients into complex geometric structures that would otherwise be impossible to produce. As a result, the process allows for drug release control at a level that that’s simply not possible with conventional tablet production techniques.

The firm has also integrated real-time Process Analytical Technology (PAT) into the MED system that can continually monitor the 3D printing process to ensure product quality and make regulatory monitoring more convenient.

Triastek的T19和T20产品已经收到FDA的研究新药(IND)清除。T19 was developed in-house and is designed to treat rheumatoid arthritis, an autoimmune disease where the body’s immune system attacks the cells that line joints by mistake, making them stiff and swollen.

The firm also boasts 158 patent applications related to 3D printed pharmaceuticals, with patent coverage in several countries around the world.

Triastek因其T19药物用于类风湿关节炎而获得了FDA的IND清除。图片通过Triastek。
c Triastek获得了印第安纳州learance from the FDA for its T19 drug for rheumatoid arthritis. Photo via Triastek.

基于协作研究

To date, Triastek has established a whole host of collaborations with multinational pharmaceutical companies to further advance its product formulations. The latest of these, the Eli Lilly partnership, will comprise a two-step program.

首先,两家公司将深入研究赋形剂和过程参数,以深入研究这些因素如何影响药物稳定性。这项研究将涵盖从配方开发到3D打印和最终药物释放阶段的所有内容。

前进,将确定联合国的合作伙伴ique 3D printable structures to design novel dosage forms. These structures will be programmed to release drugs into targetted parts of the intestines, all in a bid to improve the bioavailability of the 3D printed drugs when administered orally.

Triastek certainly isn’t the only player in the 3D printed pharmaceuticals space. Earlier this year, the venture capital arm of German chemicals firmEvonik投资于内华达州的3D印刷制药公司Laxxon Medical带来3D印刷平板电脑的批量生产更接近现实。这些公司正在合作使用Laxxon的专利3D丝网印刷技术和Evonik的专用聚合物材料来制造新颖的多药平板电脑。

在其他地方,制药技术开发人员CurifyLabsrecently partnered with food printing firm天然机器为了带来新的low-cost drug 3D printer to market。Working together, the companies say they’ve developed a “pharma-compliant’ system that offers a more efficient, automated alternative to the compounding process used to create personalized medicines.

Subscribe to the3D打印行业通讯有关增材制造中的最新消息。您也可以通过关注我们来保持联系Twitter,喜欢我们Facebook,然后调查3D打印行业YouTube Channel

寻找添加剂制造业的职业?访问3D打印作业for a selection of roles in the industry.

特色图显示了Triastek的T19药物用于类风湿关节炎。通过Triastek的照片。